Drug development and industrial pharmacy · 2025
Solubility enhancement of raloxifene hydrochloride by in situ micronization technique: physicochemical characterization and pharmacokinetic studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dayani Ladan, Varshosaz Jaleh, Emami Bafrani Jaber, Shamaeizadeh Nahal, Abolfazl Mostafavi Seyyed
Аннотация
SIGNIFICANCE: Raloxifene hydrochloride (RH) treats osteoporosis in postmenopausal women. However, due to its limited bioavailability efforts have been focused on enhancing its solubility and bioavailability.
OBJECTIVE: In this study in situ micronization have been explored to improve drug solubility through reducing particle size and enhancing saturation solubility, dissolution rate, and pharmacokinetic properties.
METHODS: D-α-tocopheryl polyethylene glycol succinate (TPGS), Solotul HS15, Cremophor® CO40, and HPMC K4M were chosen as solubility enhancing agents to produce nanocrystals via the solvent change method. The study assessed particle size, saturation solubility, and drug release rate across different formulations containing various stabilizers and concentrations.
RESULTS: Nanoparticles stabilized by 0.1% TPGS depicted the smallest particle size (467.60 ± 37.89 nm), the highest drug release in 2 h (99.61 ± 6.72%) and saturation solubility (834.11 ± 16.73 µg/mL) in comparison to pure RH and other stabilizers. Nanoparticles of RH showed Cmax of 1.86 ± 1.1 µg/mL compared to the pure crystals of RH, which showed maximum serum concentration of 0.52 ± 0.68 µg/mL. The AUC0-24 was also inclined about four times more in nanoparticles compared to the pure drug while Tmax was the same in both groups.
CONCLUSIONS: The obtained results demonstrated in situ micronization technique by solvent change method was successful in improving RH bioavailability.
OBJECTIVE: In this study in situ micronization have been explored to improve drug solubility through reducing particle size and enhancing saturation solubility, dissolution rate, and pharmacokinetic properties.
METHODS: D-α-tocopheryl polyethylene glycol succinate (TPGS), Solotul HS15, Cremophor® CO40, and HPMC K4M were chosen as solubility enhancing agents to produce nanocrystals via the solvent change method. The study assessed particle size, saturation solubility, and drug release rate across different formulations containing various stabilizers and concentrations.
RESULTS: Nanoparticles stabilized by 0.1% TPGS depicted the smallest particle size (467.60 ± 37.89 nm), the highest drug release in 2 h (99.61 ± 6.72%) and saturation solubility (834.11 ± 16.73 µg/mL) in comparison to pure RH and other stabilizers. Nanoparticles of RH showed Cmax of 1.86 ± 1.1 µg/mL compared to the pure crystals of RH, which showed maximum serum concentration of 0.52 ± 0.68 µg/mL. The AUC0-24 was also inclined about four times more in nanoparticles compared to the pure drug while Tmax was the same in both groups.
CONCLUSIONS: The obtained results demonstrated in situ micronization technique by solvent change method was successful in improving RH bioavailability.